期刊文献+

Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma 被引量:13

Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma
下载PDF
导出
摘要 AIM: To evaluate the efficacy of sequential use of transarterial chemoembolization (TACE) and percutaneous cryosurgery for unresectable hepatocellular carcinoma (HCC). METHODS: Four hundred and twenty patients were enrolled in this study. The patients, who were considered to have unresectable tumors due to their location or size or comorbidity, were divided into sequential TACE-cryosurgery (sequential) group (n = 290) and cryosurgery alone (cryoalone) group (n = 130). Patients in the sequential group tended to have larger tumors and a greater number of tumors than those in the cryo-alone group. Tumors larger than 10 cm in diameter were only seen in the sequential group. TACE was performed with the routine technique and percutaneous cryosurgery was conducted under the guidance of ultrasound 2-4 wk after TACE. RESULTS: During a mean follow-up period of 42 ± 17 mo (range, 24-70 mo), the local recurrence rateat the ablated area was 17% for all patients, 11% and 23% for patients in sequential group and cryoalone groups, respectively (P = 0.001). The overall 1-, 2-, 3-, 4and 5-year survival rate was 72%, 57%, 47%, 39% and 31%, respectively. The 1and 2-year survival rates (71% and 61%) in sequential group were similar to those (73% and 54%) in cryo-alone group (P = 0.69 and 0.147), while the 4and 5-year survival rates were 49% and 39% in sequential group, higher than those (29% and 23%) in cryo-alone group (P = 0.001). Eighteen patients with large HCC (> 5 cm in diameter) survived for more than 5 years after sequential TACE while no patient with large HCC (> 5 cm in diameter) survived more than 5 years after cryosurgery. The overall complication rate was 24%, and the complication rates were 21% and 26% for the sequential and cryo-alone groups, respectively (P = 0.06). The incidence of hepatic bleeding was higher in cryo-alone group than in sequential group (P = 0.02). Liver crack only occurred in two patients of the cryoalone group. CONCLUSION: Pre-cryosurgical TACE can increase the cryoablation efficacy and decrease its adverse effects, especially bleeding. Sequential TACE and cryosurgery may be the better procedure for unresectable HCC, especially for large HCC. AIM: To evaluate the efficacy of sequential use of transarterial chemoembolization (TACE) and percutaneous cryosurgery for unresectable hepatocellular carcinoma (HCC). METHODS: Four hundred and twenty patients were enrolled in this study. The patients, who were considered to have unresectable tumors due to their location or size or comorbidity, were divided into sequential TACE-cryosurgery (sequential) group (n = 290) and cryosurgery alone (cryoalone) group (n = 130). Patients in the sequential group tended to have larger tumors and a greater number of tumors than those in the cryo-alone group. Tumors larger than 10 cm in diameter were only seen in the sequential group. TACE was performed with the routine technique and percutaneous cryosurgery was conducted under the guidance of ultrasound 2-4 wk after TACE. RESULTS: During a mean follow-up period of 42 ± 17 mo (range, 24-70 mo), the local recurrence rate at the ablated area was 17% for all patients, 11% and 23% for patients in sequential group and cryoalone groups, respectively (P = 0.001). The overall 1-, 2-, 3-, 4- and 5-year survival rate was 72%, 57%, 47%, 39% and 31%, respectively. The 1- and 2-year survival rates (71% and 61%) in sequential group were similar to those (73% and 54%) in cryo-alone group (P = 0.69 and 0.147), while the 4- and 5-year survival rates were 49% and 39% in sequential group, higher than those (29% and 23%) in cryo-alone group (P = 0.001). Eighteen patients with large HCC (〉 5 cm in diameter) survived for more than 5 years after sequential TACE while no patient with large HCC (〉 5 cm in diameter) survived more than 5 years after cryosurgery. The overall complication rate was 24%, and the complication rates were 21% and 26% for the sequential and cryo-alone groups, respectively (P = 0.06). The incidence of hepatic bleeding was higher in cryo-alone group than in sequential group (P = 0.02). Liver crack only occurred in two patients of the cryoalone group. CONCLUSION: Pre-cryosurgical TACE can increase the cryoablation efficacy and decrease its adverse effects, especially bleeding. Sequential TACE and cryosurgery may be the better procedure for unresectable HCC, especially for large HCC.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第29期3664-3669,共6页 世界胃肠病学杂志(英文版)
基金 Supported by Scientific Foundation of Science Technology Department and Health Department of Guangdong Province
关键词 Hepatocellular carcinoma CRYOSURGERY Transarterial chemoembolization CRYOABLATION TREATMENT 冷冻治疗 肝动脉 肝癌 化疗 栓塞 序贯
  • 相关文献

参考文献2

二级参考文献21

  • 1Wolfgang Jungraithmayr,Dieter Burger,Manfred Olschewski,Stefan Eggstein.Cryoablation of malignant liver tumors: results of a single center study[J].Hepatobiliary & Pancreatic Diseases International,2005,4(4):554-560. 被引量:27
  • 2[4]Gournay J, Tchuenbou J, Richou C, Masliah C, Lerat F, Dupas B, Martin T, Nouel JF, Schnee M, Montigny P, D'Alincourt A, Hamy A, Paineau J, Le Neel JC, Le Borgne J, Galmiche JP.Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective casecontrol study with cost analysis. Aliment Pharmacol Ther 2002;16:1529-1538
  • 3[5]Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N,Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56:918-928
  • 4[6]Groupe d'Etude et de Traitement du Carcimome Hepatocelltaire.A comparison of lipiodol, chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256-1261
  • 5[7]Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 2003; 237:171-179
  • 6[8]Crews KA, Kuhn JA, McCarty TM, Fisher TL, Goldstein RM,Preskitt JT. Cryosurgical ablation of hepatic tumors. Am J Surg 1997; 174:614-618
  • 7[9]Lam CM, Yuen WK, Fan ST. Hepatic cryoablation for recurrent hepatocellular carcinoma after hepatectomy:a preliminary report.Xu KC et al. Cryoablation for hepatocellular carcinoma J Surg Oncol 1998; 68:104-106
  • 8[10]Sheen AJ, Poston GJ, Sherlock DJ. Cryotherapeutic ablation of liver tumours. Br J Surg 2002; 89:1396-1401
  • 9[11]Zhou XD, Tang ZY, Yu YQ, Ma ZC. Clinical evaluation of cryosurgery in the treatment of primary liver cancer. Report of 60 cases. Cancer 1988; 61:1889-1892
  • 10[12]Zhou XD, Tang ZY, Yu YQ, Weng JW, Ma ZC, Zhang BH, Zheng YX. The role of cryosurgery in the treatment of hepatic cancer:areport of 113 cases. J Cancer Res Clin Oncol 1993; 120:100-102

共引文献51

同被引文献82

引证文献13

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部